$18.42▴ 0.11%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Simulations Plus, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their Shareholders
[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)